Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Following a thorough analysis of our previous Phase 2b data and trial design, we believe that with the preferred modified release formulation and future trial design optimization, we can advance a competitive oral GLP-1 molecule into registration enabling studies, with the goal of addressing the present and persistent medical needs of people living with obesity. Participants in the study so far have included healthy adults aged 18 years or older and the results thus far have shown a profile that supports once-daily dosing, which is consistent with previous danuglipron studies
PlexusDx integrates genetic testing, medication history review, and glucose monitoring protocols into a personalized treatment plan
Candidate variants with the highest prevalence in the patient population were selected for functional validation
GLP-1 receptor agonist for weight loss and fertility: social media and online perception versus evidence-based medicine
US$ 22.74
US$ 21.17
US$ 20.56
US$ 28.03
US$ 24.41
US$ 29.62
